Print-Age is a POR MARCHE FESR 2014-2020 funded project (Asse 1 – Obiettivo Specifico 3 – Azione 3.1: “Promuovere soluzioni innovative per affrontare le sfide delle comunità locali nell’ambito della salute e benessere” for a total budget of about € 1.680.000 and a contribution of € 847.889,63.
The project partnership includes companies and sperimenters that are situated in Marche Region. The following companies: Diatheva, Diatech Pharmacogenetics and Mivell, in order to exploit the scientific and industrial expertise in the field of diagnostics and nutraceuticals will create a synergy through an active collaboration with leading research centers, represented by the Università di Urbino “Carlo Bo” and the Università Politecnica delle Marche. The specific objective is to develop products that will be used through an integrated approach to improve the health of the frail and elderly people, optimizing in the same moment public spending.
DIATHEVA presented a new product in pipeline "scFv 2G8" at BIO CONVENTION 2016 in the context of a workshop dedicated to showcasing of novel antibiotics which was held the past 6 June in San Francisco. Hosted by the Innovative Medicines’ Initiative (IMI), The Wellcome Trust-funded Community For Open Antimicrobial Drug Discovery and the IMI funded ENABLE project, the workshop was aimed to highlight the global tools available to support the development of novel anti-infectives coming from10 innovative company programmes from six countries.
Diatheva’s pipeline antibody-based therapies is designated to address significant unmet medical needs and by its productive technology suite capable of selecting, manufacturing in GMP compliance and characterizing innovative next generation recombinant antibody therapeutics.
Published article: Process development of a human recombinant diabody expressed in E.coli: engagment of CD99 induced apoptosis for target therapy in Ewing’s sarcoma
Target Expressed on Lymphocytes and Tumors Offers Unique Advantages for Unlocking the Immune Response to Fight Cancer
LEXINGTON, MA -- July 20, 2015 -- Agenus Inc. (NASDAQ: AGEN), an immunology company developing innovative treatments for cancers and other diseases, today announced that it has acquired rights to antibodies targeting Carcinoembryonic Antigen Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein expressed on T cell and NK cell lymphocytes from Diatheva s.r.l., an Italian biotech company controlled by SOL S.p.A.CEACAM1 is overexpressed in melanoma, bladder, lung, colon, pancreas, and gastric cancers and has been shown to modulate innate and adaptive immune suppression in pre-clinical studies. Antibodies targeting CEACAM1 are thought to have the potential to effectively treat cancer alone or in combination with other checkpoint modulator antibodies, including those in Agenus’ development pipeline.
New Italian guidelines for the prevention and control of legionellosis were approved. The document has been updated on the basis of new scientific knowledge and thanks to the technical and scientific support of the Italian Institute of Health as well as experts in this field.
The new text explains how to determine the presence of Legionella DNA in water samples according to the reference standard "Water quality-Detection and quantification of Legionella spp. and/or Legionella pneumophila by concentration and genic amplification by quantitative polymerase chain reaction (qPCR) "(ISO / TS 12869, 2012).
It’s spring , the right time for monitoring Legionella spp.
Just before the summer season and looking back over the recent cases of Legionellosis in Italy and Europe is the new time, to execute monitoring plansfor Legionella.
Diatheva proposes a molecular method for the detection and quantification of Legionella spp. in water samples more efficient,able to guarantee an improved yield,for more reliable results.
A recent paper published in the prestigious scientific journal Clinical Cancer Research entitled “ CD99 Triggering in Ewing Sarcoma Delivers a Lethal Signal through p53 Pathway Reactivation and Cooperates with Doxorubicin” demonstrates the successful scientific collaboration between DIATHEVA and Italian public research institutes (CRS Sviluppo di Terapie Biomolecolari, Istituto Ortopedico Rizzoli, Bologna; Istituto Superiore di Sanità, Roma; Università di Urbino) for the development of a new human antibody useful for treatment of Ewing sarcoma.
From now on DIATHEVA intends to support your innovative research with minimal financial risk to you. If you are interested in using one of our products in untested applications, species or instruments DIATHEVA will provide you a 50% refund on the purchased product, or a 50% discount on a future product of equal or lower value..